

RayStation selected for India's first Proton Center

Apollo Hospitals, Asia 's foremost integrated healthcare provider, as selected RayStation for a new proton therapy center in Chennai – the first such facility in India. The center will be equipped with IBA's Proteus®PLUS treatment delivery system in a multi-room configuration. The setup will comprise two gantry treatment rooms and one fixed-beam treatment room, each fitted with advanced pencil beam scanning and cone beam CT technology.

Following an extensive review of the leading systems available, RayStation was selected as the treatment planning system for the new center, which is scheduled to treat its first patients in September 2018. The choice was motivated by RayStation's comprehensive functionality and support for all major treatment delivery systems, and RaySearch's world-leading position in proton therapy treatment planning. An important goal for Apollo Hospitals is to unify the treatment planning workflow. The agreement includes modules for deformable registration, dose tracking, adaptive therapy and multi-criteria optimization.

Preetha Reddy, Vice Chairperson, Apollo Hospitals Groups says: "Our resolute commitment is to make cancer conquerable and the Apollo Proton Cancer Center in Chennai underscores this etos. Over the years, we have continuously introduced the most advanced cancer care for our patients and Apollo has been honored with the trust of individuals from over 140 countries."

Ms. Reddy added, "Innovative technologies have been a hallmark of our cancer care protocols with RayStation reaffirms our continued investments into the best available care for modalities for our patients."

Johan Löf, CEO of RaySearch, says: "We are delighted to have been chosen by Apollo Hospitals for their groundbreaking introduction of proton therapy in India. Apollo shares our view of the many benefits in having a single treatment planning system for all treatment machines, and our partnership will result in high efficiency and outstanding patient care. This installation reinforces our strong and growing presence in the APAC region and our commitment to supporting the widest possible range of treatment machines."

About Apollo Hospitals

Apollo Hospitals is widely recognized as a pioneer of private healthcare in India and established the country's first corporate hospital in 1983. Today, it is one of Asia's foremost integrated healthcare services providers, operating 64 hospitals as well as pharmacies, primary care and diagnostic clinics.

About RayStation

RayStation integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch's software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

To learn more about RaySearch, go to: www.raysearchlabs.com

For further information, please contact:

Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

Telephone: +46 (0)8-510 530 00 johan.lof@raysearchlabs.com

^{*} Subject to regulatory clearance in some markets.